Revance's Neuromodulator Injection Positive In Phase III

By Zacks Investment ResearchStock MarketsDec 06, 2017 02:10AM ET

www.investing.com/analysis/revances-neuromodulator-injection-positive-in-phase-iii-200271123

Revance's Neuromodulator Injection Positive In Phase III

By Zacks Investment Research | Dec 06, 2017 02:10AM ET

Saved. See Saved Items.

This article has already been saved in your Saved Items

AMZN

+1.55%

Add to/Remove from Watchlist

AGN

0.00%

Add to/Remove from Watchlist

ACHN_...

0.00%

Add to/Remove from Watchlist

CORT

+1.22%

Add to/Remove from Watchlist

RVNC

0.00%

Add to/Remove from Watchlist

Revance Therapeutics, Inc. (NASDAQ:RVNC) shares surged more than 33% on Dec 5 after the company announced positive top-line results from two pivotal phase III studies, evaluating its next-generation neuromodulator, RT002 (daxibotulinumtoxin), for reducing wrinkles that lies between the brows (glabellar lines).

Both the phase III studies, SAKURA 1 and SAKURA 2, met their primary and secondary endpoints, demonstrating highly statistically significant improvement in severity of glabellar lines with RT002 against placebo. Data from the study showed that RT002 delivered substantial reduction in severity of glabellar lines for a long-acting duration of six months. The candidate was generally well tolerated in both the trials.

Notably, the duration achieved by RT002 in treating glabellar lines is better than any other marketed neuromodulators which demonstrates a duration of three-four months. It is important to note that Allergan’s (NYSE:AGN) shares dropped almost 2% following the news release as RT002 is considered a potential threat to the company’s lead drug, Botox, which is marketed for the same indication. RT002 has a longer duration compared with Allergan’s Botox of five months.

Revance’s shares have significantly outperformed the industry year to date. The stock has soared 66.4% compared with the industry’s gain of 0.9% in the same time frame.

Notably, the company is conducting a long-term safety trial, SAKURA 3, on RT002 that already enrolled more than 2,500 patients across 66 sites in the United States and Canada. The study is expected to complete in the second half of 2018. If the study is successful, plans are afoot to submit regulatory applications to the FDA in the first half of 2019 with a potential launch in 2020. Per the company, RT002 will be the first neuromodulator with a long-acting duration of six months, if approved.

Per the data from Global Industry Analysts, the global aesthetic market represented revenues of about $1.6 billion in 2016 for treatments with neuromodulators. Moreover, patients and physicians consider the effect of treatment duration as the most significant component for any injectable neuromodulator. Hence, approval of the candidate is expected to cater to the hugely unmet needs of patients preferring longer duration for treatment of glabellar lines.

We remind investors that RT002 is also being evaluated in other clinical programs for different indications. Revance plans to initiate a phase III study on RT002 for treating cervical dystonia (a neurological muscle movement disorder) in 2018. RT002 was recently granted an orphan drug designation for cervical dystonia indication in the United States. Moreover, it also plans to release results from a phase II study, evaluating RT002 for management of plantar fasciitis by this year-end.

Revance Therapeutics, Inc. Price

Revance Therapeutics, Inc. Price | Revance Therapeutics, Inc. Quote

Zacks Rank & Key Picks

Revance carries a Zacks Rank #3 (Hold). Two better-ranked stocks in the health care sector are Corcept Therapeutics Incorporated (NASDAQ:CORT) and Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Corcept’s earnings per share estimates have moved up from 77 cents to 88 cents for 2018 over the last 60 days. The company delivered positive earnings surprises in two of the trailing four quarters with an average beat of 14.32%. Share price of the company has skyrocketed 127.3% year to date.

Achillion’s loss per share estimates has narrowed from 66 cents to 63 cents for 2017 and from 75 cents to 67 cents for 2018 over the last 60 days. The company came up with positive earnings surprises in two of the trailing four quarters with an average beat of 4.51%.

Wall Street’s Next Amazon (NASDAQ:AMZN)

Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.

Click for details >>

Allergan PLC. (AGN): Free Stock Analysis Report

Achillion Pharmaceuticals, Inc. (ACHN): Free Stock Analysis Report

Revance Therapeutics, Inc. (RVNC): Free Stock Analysis Report

Corcept Therapeutics Incorporated (CORT): Free Stock Analysis Report

Original post

Zacks Investment Research

Nvidia Concentration Risk: Should Retail Investors Be Worried? By Timothy Fries - Feb 28, 2025

The fortune of Nvidia (NASDAQ:NVDA) is closely tied to Big Tech hyperscalers. Although the AI/GPU designer didn’t name its largest clients in the latest 10-K filing on Wednesday,...

2 Boring Safe-Play Stocks to Protect Against Market Turmoil By Jesse Cohen - Feb 28, 2025

In a market fraught with uncertainty, investors often seek refuge in defensive-minded stocks that offer stability and resilience. Two such stalwarts, Johnson & Johnson and...

2 Stocks Riding the Dominance of America’s Natural Gas Exports By Jea Yu - Feb 28, 2025

The United States is the largest exporter of liquefied natural gas (LNG), having surpassed Australia and Qatar in 2023. The United States exports an estimated 12.5 billion cubic...

Add a Comment

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:

Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
Only English comments will be allowed.
Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I have read Investing.com's comments guidelines and agree to the terms described.

I Agree

Write your thoughts here

Are you sure you want to delete this chart?

Delete Cancel

Post

Post also to:

Replace the attached chart with a new chart ?

Replace Cancel

1000

Comment Guidelines

Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.

Please wait a minute before you try to comment again.

Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.

<div id="comment">
				<div class="comment js-comment" data-comment-id="{commentID}" id="comment-{commentID}" data-user-id="">
    <div class="mainComment js-content">
       <div class="commentInnerWrapper">
        <a href="{userLink}" class="js-user-link"><img src="{userImage}" width="33" height="33" alt="{usernameAlt}" class="img" onerror="this.src='https://i-invdn-com.investing.com/defaultUserMaleTmp.png';"></a><div class="commentBody">
                					<span class="commentUsername">
                    	<a href="{userLink}" class="js-user-link js-user-name">{username}</a>
					</span>
                                <span class="js-date" comment-date="{dateFormat}" comment-date-formatted="{dateFormatted}" title="{dateTitle}">Just Now</span>
                <div class="commentDropDown js-commentDropDownWrapper " data-user-id="" data-cid="{commentID}">
	<a href="javascript:void(0);" class="threeDotsIconSmall js-thinDropdownArrow"></a>
	<div class="tooltipPopup commentActionsPop noHeader js-commentDropDownOptions displayNone">
		<div class="addRow js-option share">
			<a href="javascript:void(0);" class="js-commentSharePopup" data-cid="{commentID}" data-curl="{commentLink}"><span class="smallShareIcon middle"></span>Share</a>
		</div>

<div class="js-option addRow follow">
            <div class="js-follow-post-button" data-reg_ep="follow comment">
                <span class="alertfollowIcon middle"></span>Follow this post            </div>
            <div class="js-unfollow-post-button displayNoneImp">
                <span class="alertUnfollowIcon middle"></span>Unfollow this post            </div>
        </div>

<div class="addRow js-option save"  data-reg_ep="save comment">
		<a href="javascript:void(0);" class="js-save-item-btn" data-item-type="comments" data-item-id="{commentID}">
			<i class="saveItemBigIcon middle"></i>
			Save		</a>
	</div>
	<div class="addRow saveItemsConfirmation noHover displayNone js-saveItemResult">
		
<div class="content js-saveItemSuccess displayNone">
	<span class="mediumGreenSuccessIcon"></span><span>Saved. See <a href="/members-admin/saved-items" target="_blank">Saved Items</a>.</span>
	<a href="javascript:void(0);" class="bugCloseIcon js-close"></a>
</div>
<div class="content js-saveItemAlreadySaved saveItemAlreadySaved displayNoneImp">
	<span>This comment has already been saved in your <a href="/members-admin/saved-items" target="_blank">Saved Items</a></span>
	<a href="javascript:void(0);" class="bugCloseIcon js-close"></a>
</div>
	</div>

<div class="addRow shareButtons js-sharePopup displayNone">
			<div class="js-shareComment"><span class="js-shareCommentSpan"></span></div>
		</div>
	</div>
</div>
                 <div class="commentAuthor js-comment-by-author"><span class="commentAuthorIcon"></span>Author's response</div>             </div>
		<div id="commentText-{commentID}" class="js-text-wrapper commentText withImage">
							<div id="commentBigChart{commentID}" class="commentBigChart js-comment-chart" onclick="openViewChartPopup('{commentID}')">
					<img src="https://d1-invdn-com.investing.com/comments_images/{commentImage}" alt="{commentAlt}">
					<i class="newMagnifyChartIcon"></i>
				</div>
						<span class="js-text">{commentContent}</span>
			<div class="clear"></div>
							<div class="commentButtons js-not-master-user">
					<a href="javascript:void(0)" class="reply js-reply-btn" data-real-parent-id="{commentID}" data-to-user-name="{username}" data-to-user-id="">Reply</a>
					<div class="inlineblock likeDislikeBox js-like-dislike-box" data-item-id="{commentID}">
	<input class="js-like-checkbox" type="checkbox" name="option" value="Yes" id="like_{commentID}">
	<label for="like_{commentID}" class="like" title="I agree"></label>
	<span class="numOfLikes js-like-count lighterGrayFont">0</span>
	<input class="js-dislike-checkbox" type="checkbox" name="option" value="No" id="dislike_{commentID}">
	<label for="dislike_{commentID}" class="dislike" title="I disagree"></label>
	<span class="numOfDislikes js-dislike-count lighterGrayFont">0</span>
</div>

<div class="reportComment js-flag float_lang_base_2">
                            <a href="javascript:void(0);" id="commentFlag_{commentID}">
                                <span class="reportCommentIcon middle"></span><span class="inlineblock middle">Report</span>
                            </a>
                        </div>
                    				</div>
					</div>
	   </div>
	</div>
	</div>			</div>
			<div id="reply">
				
    <div class="commentReply js-comment js-comment-reply" data-comment-id="{commentID}" id="comment-{commentID}" data-user-id="">
		<div class="commentInnerWrapper"><a href="{userLink}" class="js-user-link"><img src="{userImage}" width="33" height="33" alt="{usernameAlt}" class="img" onerror="this.src='https://i-invdn-com.investing.com/defaultUserMaleTmp.png';"></a><div class="commentBody js-content">
            				<span class="commentUsername">
					<a href="{userLink}" class="commentUsername js-user-link js-user-name" onMouseOver="">{username}</a>
				</span>
                        <span class="js-date" comment-date="{dateFormat}" comment-date-formatted="{dateFormatted}" title="{dateTitle}">Just Now</span>
			 <div class="commentAuthor js-comment-by-author"><span class="commentAuthorIcon"></span>Author's response</div> 			<div class="commentDropDown js-commentDropDownWrapper " data-user-id="" data-cid="{commentID}">
	<a href="javascript:void(0);" class="threeDotsIconSmall js-thinDropdownArrow"></a>
	<div class="tooltipPopup commentActionsPop noHeader js-commentDropDownOptions displayNone">
		<div class="addRow js-option share">
			<a href="javascript:void(0);" class="js-commentSharePopup" data-cid="{commentID}" data-curl="{commentLink}"><span class="smallShareIcon middle"></span>Share</a>
		</div>

</div>
		<div id="commentText-{commentID}" class="js-text-wrapper commentText withImage">
							<div id="commentBigChart{commentID}" class="replyBigChart displayNone js-comment-chart">
					<img src="https://d1-invdn-com.investing.com/comments_images/{commentImage}" alt="{commentAlt}">
					<i class="newMagnifyChartIcon"></i>
				</div>
				<span id="commentSmallChart{commentID}" class="commentSmallChart pointer js-comment-chart" onclick="openViewChartPopup('{commentID}')">
                    <img src="https://d1-invdn-com.investing.com/comments_images/{commentImageSmall}" width="116" height="52" alt="{commentAlt}">
                    <span class="chartMagnifyOverlay displayNone"></span>
                    <span class="searchGlassIcon chartMagnify displayNone"></span>
                </span>
						<span class="js-text">{commentContent}</span>
			<div class="clear"></div>
							<div class="commentButtons js-not-master-user">
					<a href="javascript:void(0)" class="reply js-reply-btn" data-real-parent-id="{commentID}" data-to-user-name="{username}" data-to-user-id="">Reply</a>
					<div class="inlineblock likeDislikeBox js-like-dislike-box" data-item-id="{commentID}">
	<input class="js-like-checkbox" type="checkbox" name="option" value="Yes" id="like_{commentID}">
	<label for="like_{commentID}" class="like" title="I agree"></label>
	<span class="numOfLikes js-like-count lighterGrayFont">0</span>
	<input class="js-dislike-checkbox" type="checkbox" name="option" value="No" id="dislike_{commentID}">
	<label for="dislike_{commentID}" class="dislike" title="I disagree"></label>
	<span class="numOfDislikes js-dislike-count lighterGrayFont">0</span>
</div>

Are you sure you want to delete this chart?

Delete Cancel

Post

Replace the attached chart with a new chart ?

Replace Cancel

1000

Comment Guidelines

Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.

Please wait a minute before you try to comment again.

I feel that this comment is:

Spam

Offensive

Thank You!

Your report has been sent to our moderators for review

Central Banks

Interest Rates

Next Meeting

FED

4.50%

Mar 19, 2025

ECB

2.90%

Mar 06, 2025

BOE

4.50%

Mar 20, 2025

SNB

0.50%

Mar 20, 2025

RBA

4.10%

Apr 01, 2025

BOC

3.00%

Mar 12, 2025

RBNZ

3.75%

Apr 09, 2025

BOJ

0.50%

Mar 19, 2025

CBR

21.00%

Mar 21, 2025

RBI

6.25%

Mar 10, 2025

PBOC

3.10%

BCB

13.25%

Mar 19, 2025

US 30	43,783.5	+543.4	+1.26%
US 500	5,947.4	+85.7	+1.46%
Dow Jones	43,839.99	+600.49	+1.39%
S&P 500	5,954.39	+92.82	+1.58%
Nasdaq	18,847.28	+302.86	+1.63%
S&P 500 VIX	19.63	-1.50	-7.10%
Dollar Index	107.500	+0.324	+0.30%

Crude Oil WTI	69.93	-0.42	-0.60%
Brent Oil	73.03	-0.54	-0.73%
Natural Gas	3.816	-0.118	-3.00%
Gold	2,868.41	-27.49	-0.95%
Silver	31.433	-0.368	-1.16%
Copper	4.5598	-0.0587	-1.27%
US Soybeans	1,011.50	-11.25	-1.10%

U.S. 10Y	4.204	-0.083	-1.94%
U.S. 30Y	4.490	-0.064	-1.41%
U.S. 5Y	4.016	-0.089	-2.17%
U.S. 3M	4.305	-0.006	-0.14%
US 10Y T-Note	111.16	+0.55	+0.49%
Euro Bund	133.29	+0.40	+0.30%
10-2 Yield Spread	17.88	-1.73	-8.82%

Apple	241.84	+4.10	+1.73%
Alphabet A	170.28	+1.75	+1.04%
Tesla	292.98	+11.10	+3.94%
Amazon.com	212.28	+3.23	+1.55%
Netflix	980.56	+17.49	+1.82%
Meta Platforms	668.20	+9.96	+1.51%
Bank of America	46.10	+1.98	+4.49%

Revance's Neuromodulator Injection Positive In Phase III

Related Articles